On sickle cell, Q4 framed the pre-sNDA meeting as pending to define pathway, while Q1 updated to a specific action and timing: CEO Goff said Agios “plan [s] to submit an sNDA…in the second quarter ...
The latest Chinese model trails U.S. competitors on benchmarks. But it may not have to win the performance race to reshape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results